With a new law that makes it easier for people to access experimental treatments, Montana could become the hub for the ...

A second-generation anti-CD40 therapy that inhibits B- and T-cell activity nearly eliminated multiple sclerosis activity over ...

Under the new law, anyone in Montana can legally access drugs that have passed just one phase 1 clinical trial.